A study of the association between hormone replacement therapy, smoking and the occurence of myocardial infarction in women.
The initial results are reported of a case-control study undertaken on the VAMP multi-purpose database and designed to estimate the risk for first-time occurrence of myocardial infarction in users of hormone replacement therapy (HRT).
The findings currently available relate to the computerized data and show 2- to 5-fold increases in risk in smokers and those with diabetes mellitus, hypertension or hyperlipidaemia.
With any form of HRT, a non-significant protective effect [adjusted odds ratio=0.83 with 95% CI (confidence intervals) of 0.66-1.03, p=0.089] has been shown.
However, the protective effect of HRT in the data available to date appears to be confined to non-smokers in whom the odds ratio in the absence of other risk factors is 0.70 (95% CI of 0.49-1.00).
Mots-clés Pascal : Infarctus, Myocarde, Homme, Femelle, Chimiothérapie, Traitement, Hormone, Tabagisme, Facteur risque, Royaume Uni, Europe, Epidémiologie, Cardiopathie coronaire, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Infarct, Myocardium, Human, Female, Chemotherapy, Treatment, Hormone, Tobacco smoking, Risk factor, United Kingdom, Europe, Epidemiology, Coronary heart disease, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0314115
Code Inist : 002B12A03. Création : 199406.